AI won't fix clinical development until pharma changes how they use it

Clinical development has matured through decades of scientific progress and hard‑won experience, but the weight of that knowledge has made decision‑making more complex than it should be. Across pharma, familiar friction accumulates: evidence is scattered across systems and teams; decisions stall while context is repeatedly rebuilt; documentation multiplies faster than confidence; and routine “status” becomes work in its own right. The result is not just inefficiency, but late trade-offs, avoidable rework, and decisions that are revisited because they were never reached in a truly data-informed, defensible way.

AI can help, but only if it is applied to the actual constraints of running trials in a regulated environment. That means moving beyond generic tools and isolated pilots toward a role-based operating model that supports how clinical development decisions are formed, documented, and executed.

You’ll often hear certain research or intelligence platforms cited as early signals of AI adoption in pharma because they make external research dramatically faster and more citable. That’s a useful example, but limited adoption translates to limited impact. The larger lesson is that AI creates value in clinical development when it consistently and repeatably strengthens a small number of core capabilities that map directly to how pharma run programs day-to-day.

This article lays out a practical AI stack across four components, and a 30-to-60-day playbook to start capturing value from investments in AI. This well help pharma to move beyond experimentation and recognize the rewards of reduced resource demands and cycle times – ultimately leading to more rapid results from regulators.

Picture a Phase II program approaching protocol finalization. The team debates tightening inclusion criteria to improve signal clarity. A reasonable question arises: have competitors successfully recruited similar populations, and have regulators raised concerns in related filings? Over the following weeks, parallel groups commission desk research, search trial registries, and assemble slides in isolation. When the team reconvenes, the evidence is partial, hard to compare, and still inconclusive. Meanwhile, the downstream effects on feasibility, site selection, and timelines are not fully examined until months later, when recruitment stalls and a protocol amendment becomes likely.

These setbacks at a team or asset-level risk being dismissed as misfortune or isolated unpredictable events, but repetition across the sector points to a systemic challenge related to how we design and execute trials. . Evidence, analysis, documentation, and execution are treated as separate activities and stitched together manually. By deploying AI the same way pharma deploy other capabilities: explicitly by function, workflow, and accountability, biopharma can create an AI stack that removes friction and returns focus to accelerating asset development.

Pharma see the greatest returns when they think about AI as a small stack of complementary capabilities rather than as a single solution. Each layer supports a different set of roles and decisions:

1. Evidence and signal - What is the clinical and regulatory precedent - and is the evidence sufficient to support this decision?
2. Work production - How do we translate decisions into clear, consistent clinical documentation and deliverables?
3. Analysis and build - How do we generate reliable analyses and interpretable results without delaying timelines?
4. Orchestration - How do we progress studies predictably across functions, sites, and vendors?

Evidence and signal capabilities address the persistent challenge of precedent. Clinical strategy, trial design, and regulatory teams regularly need to answer questions such as what competitors are doing, how regulators have responded in similar situations, and what patterns appear across filings or publications. No single source answers all of these questions well. Mature pharma have developed custom AI solutions that combine external research platforms, trial intelligence databases, literature search tools, and regulatory references, then standardize how insights are captured. The key output is an evidence pack: a concise articulation of a question, the sources consulted, the confidence in the conclusion, and the implications for design or risk. The goal is not more research, but faster, more defensible decisions.

Work production capabilities focus on the volume and consistency of clinical documentation. Medical writers, regulatory leads, and program teams produce protocols, briefing books, decision memos, and weekly updates at high pace when supported by and trained to in new AI-enabled workflows. Productivity copilots and controlled writing assistants can help by accelerating first drafts, enforcing consistency, and enabling reuse of approved language. The real value does not come from speed alone, but from reducing rework and variation across documents that must ultimately tell a single, coherent story.

Analysis and build capabilities matter most for biostatistics, data management, and analytics teams. Here, the bottleneck is rarely insight; it is cycle time and quality assurance. Coding copilots, notebook assistants, and automated test frameworks can shorten analysis cycles by supporting reproducible pipelines, embedded checks, and standard templates. Used well, these tools reduce late-stage QC findings and make analyses easier to audit and explain.

Orchestration capabilities address the execution layer of development programs. Clinical operations, PMO, quality, and TMF teams spend significant time on status tracking, action follow-up, and dependency management. Workflow automation and agent-based orchestration can turn meeting notes into action logs, generate consistent status packs, flag missing TMF artifacts, and surface risks earlier. Because these activities are highly repeatable, this layer often delivers value fastest.

Rather than attempting an enterprise rollout, pharma should start with a small number of tightly scoped pilots mapped to the stack. One effective starting point is a weekly evidence brief for priority programs, synthesizing competitor and regulatory signals into a concise decision-ready summary. Another is an automated study status pack that draws from milestones, risks, and actions to give leadership a consistent view of progress without manual assembly. A third is an analysis and QC accelerator for data and biostatistics teams, built around reproducible templates and automated checks in a controlled environment. Each of these pilots can be implemented quickly, without replacing core systems, and measured through tangible outcomes rather than adoption metrics.

The right measures sit squarely in the domain of clinical development, not AI. Pharma should look at whether decision latency is falling, whether documents require fewer revision cycles, whether manual handoffs are decreasing, and whether operational stability is improving. Inspection readiness and audit burden are particularly telling indicators.

Supporting this, governance designed for AI is crucial and can be designed to accelerate work rather than constrain it. Role-based access and clear separation of environments protect sensitive data; built-in traceability ensures that sources, versions, and reviewers are explicit; and human accountability for decisions remains clear to align with regulatory expectations.

As AI-products continue to flood the market, some tools attract attention early because they remove obvious friction from evidence discovery. Others are equally important in drafting, analysis, and execution. The real opportunity for pharma lies in connecting these capabilities in a way that enhances their existing clinical infrastructure and workflows.

Pharma who get this right will not simply adopt AI. They will design a clinical development engine that makes better decisions faster, with less rework and stronger defensibility, while keeping accountability and compliance exactly where they belong.

This article was first published in Clinical Leader.